Literature DB >> 7773225

Treatment of leukemia relapse after bone marrow transplantation with interferon-alpha and interleukin 2.

L Shaffer1, S Giralt, R Champlin, K W Chan.   

Abstract

A 16-year-old girl with refractory AML received unmanipulated BMT from an unrelated donor. Leukemia relapse occurred 82 days later. The patient was then treated with IL-2 1.8 x 10(6) U/m2 for 5 days per week and 2.5 MU/m2 IFN-alpha three times per week. Toxicities included fever, skin rash, somnolence and a generalized seizure. Treatment was stopped after 2 weeks. Acute GVHD developed at the end of therapy and the patient's leukemia went into remission. She died of fungal pneumonia 30 days later. We conclude that a combination of cytokines may be useful in treating relapsed leukemia after BMT.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7773225

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  Successful reduced-intensity stem cell transplantation from an HLA haploidentical 3-loci-mismatched donor on the basis of fetomaternal microchimerism in a patient with advanced acute myeloid leukemia.

Authors:  Nobuhiko Uoshima; Yuri Kamitsuji; Etsuko Maruya; Hiroh Saji
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

2.  Preemptive Interferon-α Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies.

Authors:  Meng-Zhu Shen; Xiao-Hui Zhang; Lan-Ping Xu; Yu Wang; Chen-Hua Yan; Huan Chen; Yu-Hong Chen; Wei Han; Feng-Rong Wang; Jing-Zhi Wang; Xiao-Su Zhao; Ya-Zhen Qin; Ying-Jun Chang; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Dong Mo
Journal:  Front Immunol       Date:  2022-01-28       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.